MICROWAVE TREATMENT OF LOCALIZED PROSTATE CANCER

Information

  • Research Project
  • 6143085
  • ApplicationId
    6143085
  • Core Project Number
    R43CA086656
  • Full Project Number
    1R43CA086656-01
  • Serial Number
    86656
  • FOA Number
  • Sub Project Id
  • Project Start Date
    3/1/2000 - 24 years ago
  • Project End Date
    2/28/2001 - 23 years ago
  • Program Officer Name
    STONE, HELEN B.
  • Budget Start Date
    3/1/2000 - 24 years ago
  • Budget End Date
    2/28/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    1
  • Suffix
  • Award Notice Date
    2/28/2000 - 24 years ago
Organizations

MICROWAVE TREATMENT OF LOCALIZED PROSTATE CANCER

Prostatic cancer is the second leading cause of cancer mortality in U.S. men. The proposed program is directed at developing novel instrumentation and procedures that will safely produce uniform therapeutic hyperthermic temperatures in prostate glands to improve the survival rates in patients with localized prostate cancer. The instrumentation will broadcast microwave power into the prostate gland from two separate microwave balloon catheters -- one in the urethra and one in the rectum. The prostate gland is one of the few organs treatable with microwave hyperthermia from more than one direction. The proposed approach will do this to provide more uniform heating than possible from either applicator alone. A new type of urethral microwave balloon catheter will be developed in which the microwave applicator and the expansion catheter are a single integrated assembly improving antenna efficiency and reducing catheter diameter for patient comfort. The urethral dilation under heating will also provide treatment for BPH at the same time -- creating a biological stent. The rectal microwave balloon catheter will be of a completely new design in which the expansion balloon will force the antenna element against the rectal wall proximate the prostate thereby compressing it and improving treatment efficacy. PROPOSED COMMERCIAL APPLICATIONS: Prostatic cancer affects many men and the overall treatment costs are extremely high. The proposed approach has the potential for providing an adjuvant treatment that may be performed on an "out-patient" basis to improve the survival rates in patients being treated with external beam or implant therapy radiation. The new type of catheters developed during the proposed program and the associated hyperthermia equipment will be important commercial products.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    98832
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    395
  • Ed Inst. Type
  • Funding ICs
    NCI:98832\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    MMTC, INC.
  • Organization Department
  • Organization DUNS
    362918591
  • Organization City
    PRINCETON
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    08540
  • Organization District
    UNITED STATES